BR112022022331A2 - Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente - Google Patents
Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um pacienteInfo
- Publication number
- BR112022022331A2 BR112022022331A2 BR112022022331A BR112022022331A BR112022022331A2 BR 112022022331 A2 BR112022022331 A2 BR 112022022331A2 BR 112022022331 A BR112022022331 A BR 112022022331A BR 112022022331 A BR112022022331 A BR 112022022331A BR 112022022331 A2 BR112022022331 A2 BR 112022022331A2
- Authority
- BR
- Brazil
- Prior art keywords
- psychedelic
- composition
- positive
- patient
- therapeutic effects
- Prior art date
Links
- 230000001337 psychedelic effect Effects 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000008092 positive effect Effects 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 101150104779 HTR2A gene Proteins 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MÉTODO PARA MELHORAR EFEITOS TERAPÊUTICOS POSITIVOS DE UM PSICODÉLICO, COMPOSIÇÃO, E MÉTODO PARA TRATAR UM PACIENTE. Trata-se de um método para melhorar os efeitos positivos de um psicodélico, por indução de um estado psicológico positivo em um indivíduo com um empatógeno/entactógeno, administração de um psicodélico ao indivíduo e melhora de uma resposta positiva ao psicodélico. Uma composição que inclui um entactógeno/empatógeno e um psicodélico serotonérgico na mesma forma de dosagem ou administrada como composições separadas dentro de um cronograma de tratamento de combinação. Um método para melhorar os efeitos positivos de um psicodélico, por indução da liberação de monoaminas endógenas, e estimular subsequentemente os receptores os receptores de 5-HT2A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020261P | 2020-05-05 | 2020-05-05 | |
| PCT/US2021/028707 WO2021225796A1 (en) | 2020-05-05 | 2021-04-22 | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022331A2 true BR112022022331A2 (pt) | 2022-12-20 |
Family
ID=78411861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022331A BR112022022331A2 (pt) | 2020-05-05 | 2021-04-22 | Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11963946B2 (pt) |
| EP (1) | EP4138815A4 (pt) |
| JP (1) | JP2023524764A (pt) |
| KR (1) | KR20230006554A (pt) |
| CN (1) | CN115811975A (pt) |
| AU (1) | AU2021267101B2 (pt) |
| BR (1) | BR112022022331A2 (pt) |
| CA (1) | CA3177582A1 (pt) |
| IL (1) | IL297912A (pt) |
| WO (1) | WO2021225796A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021067626A2 (en) | 2019-10-01 | 2021-04-08 | Intima Bioscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
| WO2021225796A1 (en) * | 2020-05-05 | 2021-11-11 | Universitätsspital Basel | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
| JP2023530092A (ja) | 2020-06-08 | 2023-07-13 | タクトジェン インコーポレイテッド | 精神障害又は精神高揚に有利なベンゾフラン組成物 |
| WO2021250434A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| EP4301464A1 (en) * | 2021-03-06 | 2024-01-10 | Universitätsspital Basel | Using geno- or phenotyping to adjust lsd dosing |
| WO2023012524A2 (en) * | 2021-08-03 | 2023-02-09 | Universitatsspital Basel | Lsd and psilocybin dose equivalence determination |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| WO2024064825A1 (en) * | 2022-09-21 | 2024-03-28 | Axsome Therapeutics, Inc. | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| GB202214721D0 (en) * | 2022-10-06 | 2022-11-23 | Rewire Therapeutics Ltd | A treatment for mental disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2134330T3 (da) * | 2007-03-19 | 2013-08-05 | Acadia Pharm Inc | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika |
| WO2016199135A1 (en) | 2015-06-08 | 2016-12-15 | Sipnose Ltd | An improved capsule for delivering flowable substance |
| AU2018217829A1 (en) | 2017-02-09 | 2019-09-12 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| EP3661491A1 (en) * | 2017-08-03 | 2020-06-10 | Mind Medicine, Inc. | Use of 3-methylmethcathinone |
| AU2020215150A1 (en) | 2019-01-30 | 2021-09-09 | Diamond Therapeutics Inc | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| CN110927314A (zh) * | 2019-12-06 | 2020-03-27 | 公安部物证鉴定中心 | 一种新精神活性物质5,6-mdai的检测方法 |
| JP2023515616A (ja) * | 2020-02-28 | 2023-04-13 | ユニヴェルシテートスピタル バーゼル | ５ｈｔ２ａアゴニストの投与後の抑制効果 |
| US20230126036A1 (en) | 2020-04-01 | 2023-04-27 | The Regents Of The University Of California | Molecularly-Initiated, Experientially-Delivered Treatments and Systems for Practicing Same |
| CA3175211A1 (en) * | 2020-04-13 | 2021-10-21 | Matthias Emanuel LIECHTI | Lsd dose identification |
| WO2021225796A1 (en) * | 2020-05-05 | 2021-11-11 | Universitätsspital Basel | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
| WO2021257169A1 (en) * | 2020-06-15 | 2021-12-23 | Universitätsspital Basel | Mdma response prediction |
| EP4192451A1 (en) * | 2020-08-05 | 2023-06-14 | Universitätsspital Basel | Intravenous dmt administration method for dmt-assisted psychotherapy |
-
2021
- 2021-04-22 WO PCT/US2021/028707 patent/WO2021225796A1/en unknown
- 2021-04-22 AU AU2021267101A patent/AU2021267101B2/en active Active
- 2021-04-22 CN CN202180046825.5A patent/CN115811975A/zh active Pending
- 2021-04-22 KR KR1020227042222A patent/KR20230006554A/ko unknown
- 2021-04-22 IL IL297912A patent/IL297912A/en unknown
- 2021-04-22 JP JP2022567234A patent/JP2023524764A/ja active Pending
- 2021-04-22 EP EP21800804.3A patent/EP4138815A4/en active Pending
- 2021-04-22 CA CA3177582A patent/CA3177582A1/en active Pending
- 2021-04-22 BR BR112022022331A patent/BR112022022331A2/pt unknown
- 2021-04-22 US US17/238,088 patent/US11963946B2/en active Active
- 2021-12-13 US US17/549,807 patent/US11364221B2/en active Active
-
2023
- 2023-03-06 US US18/178,703 patent/US20230201160A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4138815A4 (en) | 2024-04-24 |
| CA3177582A1 (en) | 2021-11-11 |
| WO2021225796A1 (en) | 2021-11-11 |
| AU2021267101B2 (en) | 2024-03-28 |
| AU2021267101A1 (en) | 2022-12-01 |
| US20210346341A1 (en) | 2021-11-11 |
| US11364221B2 (en) | 2022-06-21 |
| CN115811975A (zh) | 2023-03-17 |
| US20220096429A1 (en) | 2022-03-31 |
| EP4138815A1 (en) | 2023-03-01 |
| JP2023524764A (ja) | 2023-06-13 |
| KR20230006554A (ko) | 2023-01-10 |
| IL297912A (en) | 2023-01-01 |
| US11963946B2 (en) | 2024-04-23 |
| US20230201160A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022331A2 (pt) | Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| AR058359A1 (es) | Combinaciones | |
| BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| RS54561B1 (en) | COMPOSITION FOR CONTROLLED Ovarian Stimulation | |
| CL2016001794A1 (es) | Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon. | |
| BR112023002453A2 (pt) | Composições de agente de via de estresse de replicação e métodos para tratar câncer | |
| BR112013031117A8 (pt) | Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos. | |
| BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
| BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
| BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
| BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
| BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112022014911A2 (pt) | Composição de saúde articular e uso da mesma em mamíferos saudáveis | |
| BR112023024701A2 (pt) | Métodos de tratamento de doenças do fígado | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| ECSP23066120A (es) | Agonistas del receptor de amilina de acción prolongada y usos de estos | |
| BR112014025990A2 (pt) | preparação e método para a profilaxia e tratamento de osteoporose atípica | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante |